A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

Who May Qualify: - diagnosed by tissue sample (biopsy-confirmed) Hepatocellular carcinoma (HCC) - Subjects with HCC who have received standard systemic therapies - HLA-A \*02 - BCLC stage B or C - Child-pugh score ≤ 7 ol - Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be ≤ 1 × 1000 IU/ml - Have at least one measurable leasion at baseline as per mRECIST and iRECIST - Life expectancy of 3 months or greater - The organ function is in good condition. Who Should NOT Join This Trial: - Subjects with history of another primary cancer within 5 years - Central nervous system metastasis and clinically significant central nervous system disease - Previous or current coexistence of hepatic encephalopathy - Currently present with symptomatic third space fluid accumulation - Hypertension that is poorly controlled, as determined by researchers (i.e., arterial hypertension that remains uncontrolled despite standard treatment) - Known history of neurological or mental disorder, including epilepsy or dementia - Suffering from active autoimmune conditions (where your immune system attacks your own body)s, or other significant ongoing immune rejection based on pathology and clinical diagnosis - Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy - Positive for HCV - RNA test or positive for HAV IgM antibody or positive for HDV IgM antibody; or there is current evidence indicating the presence of HEV infection - Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine) - Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation Always talk to your doctor about whether this trial is right for you.